Toxicology labs face tough times
Deep cuts in Medicare reimbursements and competition from a few huge national chains and walk-in labs are making it tougher for Indianapolis-based AIT and other toxicology labs to compete.
Deep cuts in Medicare reimbursements and competition from a few huge national chains and walk-in labs are making it tougher for Indianapolis-based AIT and other toxicology labs to compete.
You can't escape drug ads, as pervasive as they are. But did you know there's an annual banquet to award the best of the lot?
Lilly got a boost from a stable of new drugs but saw sales tumble for longtime stalwarts Cymbalta and Humalog. Meanwhile, R&D costs rose as the company ushered products through its late-stage pipeline.
Many big donors who helped propel Republican Mike Pence into the Governor’s Office appear to be sitting out his re-election effort or are waiting to write checks.
The case for broad, state funding for preschool has always been strong. Three recent developments make it overwhelming. First, Marion County families are demanding high-quality preschool for their children. For the second straight year, there have been more than twice as many applications for financial support as there are available scholarships. Parents care about their […]
Bristol-Myers Squibb Co.’s blockbuster cancer drug Opdivo prolonged survival in cases of recurrent head and neck cancer, a first for patients with the harshest form of the disease who often face a bleak prognosis.
Hundreds of admirers took to Facebook to remember Helen Wells, who started her agency in 1980 and provided talent to many of Indiana's top companies.
This is an industry worth protecting, whether for economic reasons or for the benefits to patients worldwide.
Upon his arrival in Indianapolis, Clowes began aggressively pursuing research that might lead to mass-produced pharmaceuticals.
On July 1, Indiana will join 46 states in allowing physicians to write prescriptions after talking to patients on their laptops or smartphones, with no office visit required.
Despite numerous setbacks in finding a treatment for the disease in recent years, the Indianapolis drugmaker is gearing up for another big clinical trial.
Indiana University Health hopes its $1 billion plan to expand Methodist Hospital will spawn nearby development, creating an area where employees can live adjacent to where they work.
The three drugmakers that dominate the world diabetes market—Eli Lilly and Co., Novo Nordisk A/S and Sanofi—are introducing improved forms of insulin, with a price tag to match.
Under Eli Lilly’s insurance policy, the National Union Fire Insurance Co. paid the drug firm more than $42 million for loss of the drugs, damage to the property and other expenses. The insurer’s lawsuit sought to recoup the money from the security firm.
The Senate easily passed a bill Monday allowing corporations to make a federal case of the theft of trade secrets, but a broader patent-law overhaul backed by businesses including Eli Lilly and Co. faces a rougher road.
Several central Indiana groups already have received millions of dollars from Skill UP to give students and workers the training they need to fill jobs that are in high demand.
Within six months, Eli Lilly and Co. could know whether the Food and Drug Administration has approved its latest drug, baricitinib, a once-a-day tablet for treating rheumatoid arthritis.
For Eli Lilly and Co., the approval rewards a decade-long effort to re-enter the biotech and autoimmune spaces that it helped pioneer in the 1980s but then abandoned in the 1990s.
Another surge in U.S. stocks Thursday, on the heels of a four-week rally, turned the Dow Jones industrial average positive for the year and wiped out its losses from a terrible start to 2016.